An association between Crohn's disease (CD) and hepatic steatosis has been reported. However, the underlying mechanisms of steatosis progression in CD are not clear. Among the most effective CD treatments are agents that inhibit Tumor-Necrosis-Factor (TNF) activity, yet it is unclear why anti-TNFα agents would affect steatosis in CD. Recent studies suggest that microbiome can affect both, CD and steatosis pathogenesis. Therefore, we here analysed a potential relationship between anti-TNF treatment and hepatic steatosis in CD, focusing on the gut-liver axis.

中文翻译：

---

克罗恩病中的抗 TNFα 治疗：对肝脂肪变性、肠源性激素和代谢状态的影响

据报道，克罗恩病 (CD) 与肝脂肪变性之间存在关联。然而，CD 中脂肪变性进展的潜在机制尚不清楚。最有效的 CD 治疗方法是抑制肿瘤坏死因子 (TNF) 活性的药物，但尚不清楚为什么抗 TNFα 药物会影响 CD 的脂肪变性。最近的研究表明，微生物组可以影响 CD 和脂肪变性的发病机制。因此，我们在这里分析了抗 TNF 治疗与 CD 肝脂肪变性之间的潜在关系，重点是肠肝轴。